Revenue swung from $115.5M in Q3 2025 to $51.7M in Q1 2026 and operating margin moved from 33.6% to -20.0% in Q3 2026, suggesting lumpy royalty recognition and thin operating conversion despite high gross margins near 96%.
Ligand Pharmaceuticals Incorporated (LGND) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Sales/Revenue | 253.83M | 268.09M | 167.13M | 131.31M | 196.25M | 241.54M | 163.56M | 120.28M | 251.45M | 141.1M | 108.97M | 71.91M | 64.54M | 48.97M | 31.39M | 30.04M | 23.54M | 38.94M | 27.32M | 12.89M | 140.96M | 176.61M | 163.51M | 141.14M | 96.64M | 76.34M | 48.11M | 40.9M | 17.7M | 51.7M | 36.8M |
| Revenue Growth % | 1.03% | 60.4% | 27.28% | -33.09% | -18.75% | 47.68% | 35.98% | -52.17% | 78.21% | 29.48% | 51.53% | 11.43% | 31.78% | 56.03% | 4.5% | 27.61% | -39.55% | 42.56% | 111.84% | -90.85% | -20.18% | 8.01% | 15.85% | 46.05% | 26.59% | 58.68% | 17.63% | 131.07% | -65.76% | 40.49% | 50.2% |
| Cost of Goods Sold | -18.05M | 6.59M | 11.07M | 35.05M | 52.83M | 62.18M | 30.42M | 11.35M | 6.34M | 5.37M | 5.57M | 5.81M | 9.14M | 5.73M | 3.6M | 4.91M | 0 | 15.23M | 0 | 0 | 22.64M | 39.85M | 39.8M | 31.62M | 20.31M | 13.95M | 1.62M | 3.1M | -7.7M | -9.8M | -9.4M |
| COGS % of Revenue | - | 2.46% | 6.63% | 26.69% | 26.92% | 25.74% | 18.6% | 9.43% | 2.52% | 3.8% | 5.11% | 8.07% | 14.16% | 11.71% | 11.47% | 16.34% | - | 39.12% | - | - | 16.06% | 22.56% | 24.34% | 22.4% | 21.01% | 18.27% | 3.36% | 7.58% | -43.5% | -18.96% | -25.54% |
| Gross Profit | 271.88M | 261.5M | 156.06M | 96.27M | 143.42M | 179.37M | 133.14M | 108.94M | 245.12M | 135.74M | 103.4M | 66.11M | 55.4M | 43.24M | 27.79M | 25.13M | 23.54M | 23.7M | 27.32M | 12.89M | 118.32M | 136.76M | 123.71M | 109.52M | 76.33M | 62.39M | 46.49M | 37.8M | 25.4M | 61.5M | 46.2M |
| Gross Margin % | 107.11% | 97.54% | 93.37% | 73.31% | 73.08% | 74.26% | 81.4% | 90.57% | 97.48% | 96.2% | 94.89% | 91.93% | 85.84% | 88.29% | 88.53% | 83.66% | 100% | 60.88% | 100% | 100% | 83.94% | 77.44% | 75.66% | 77.6% | 78.99% | 81.73% | 96.64% | 92.42% | 143.5% | 118.96% | 125.54% |
| Gross Profit Growth % | - | 67.56% | 62.11% | -32.88% | -20.04% | 34.72% | 22.22% | -55.56% | 80.58% | 31.27% | 56.42% | 19.32% | 28.12% | 55.62% | 10.58% | 6.75% | -0.7% | -13.22% | 111.84% | -89.1% | -13.49% | 10.55% | 12.95% | 43.48% | 22.34% | 34.2% | 22.99% | 48.82% | -58.7% | 33.12% | 63.83% |
| Operating Expenses | 241.64M | 214.3M | 178.66M | 84.32M | 140.38M | 75.52M | 95.64M | -698.14M | 81.39M | 67.66M | 58.48M | 37.76M | 34.69M | 27.26M | 26.9M | 25.27M | 51.79M | 70.32M | 52.59M | 73.07M | 287.09M | 163.23M | 161.08M | 128.7M | 100.48M | 85.53M | 92.37M | 94.1M | 95M | 92.3M | 79.1M |
| OpEx % of Revenue | - | 79.94% | 106.9% | 64.21% | 71.53% | 31.26% | 58.48% | -580.42% | 32.37% | 47.95% | 53.67% | 52.5% | 53.75% | 55.66% | 85.7% | 84.12% | 220.03% | 180.58% | 192.54% | 566.69% | 203.67% | 92.43% | 98.51% | 91.19% | 103.98% | 112.04% | 192.01% | 230.07% | 536.72% | 178.53% | 214.95% |
| Selling, General & Admin | 147.6M | 92.45M | 78.65M | 52.79M | 70.06M | 46.79M | 60.01M | 41.88M | 37.73M | 28.65M | 26.62M | 24.38M | 22.57M | 17.98M | 16.11M | 14.98M | 29.72M | 15.21M | 23.79M | 30.41M | 248.28M | 107.16M | 95.88M | 61.02M | 41.68M | 34.43M | 34.11M | 27.3M | 16.6M | 10.1M | 10.2M |
| SG&A % of Revenue | - | 34.48% | 47.06% | 40.2% | 35.7% | 19.37% | 36.69% | 34.82% | 15.01% | 20.31% | 24.43% | 33.9% | 34.97% | 36.72% | 51.32% | 49.86% | 126.28% | 39.06% | 87.08% | 235.85% | 176.14% | 60.68% | 58.63% | 43.23% | 43.13% | 45.1% | 70.91% | 66.75% | 93.79% | 19.54% | 27.72% |
| Research & Development | 23.09M | 81.18M | 21.43M | 24.54M | 36.08M | 32.1M | 40.5M | 55.91M | 27.86M | 26.89M | 21.22M | 13.38M | 12.12M | 9.27M | 10.79M | 10.29M | 22.07M | 39.87M | 30.77M | 44.62M | 41.93M | 56.08M | 65.2M | 67.68M | 58.81M | 51.1M | 51.29M | 59.4M | 70.7M | 72.4M | 59.5M |
| R&D % of Revenue | - | 30.28% | 12.82% | 18.69% | 18.39% | 13.29% | 24.76% | 46.48% | 11.08% | 19.05% | 19.47% | 18.61% | 18.78% | 18.94% | 34.38% | 34.26% | 93.75% | 102.39% | 112.65% | 346.08% | 29.74% | 31.75% | 39.88% | 47.95% | 60.85% | 66.94% | 106.6% | 145.23% | 399.44% | 140.04% | 161.68% |
| Other Operating Expenses | 4M | 40.67M | 78.59M | 7M | 34.24M | -3.38M | -4.87M | -795.93M | 15.79M | 12.12M | 10.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.96M | -1.96M | -3.12M | 0 | 0 | 0 | 0 | 0 | 6.97M | 7.4M | 7.7M | 9.8M | 9.4M |
| Operating Income | 30.24M | 47.2M | -22.61M | 11.94M | 3.04M | 103.85M | 37.5M | 807.08M | 163.73M | 68.08M | 43.88M | 27.33M | 19.63M | 14.94M | 574K | -698K | -29.3M | -9.97M | -97.28M | -60.17M | -168.77M | -26.47M | -37.37M | -19.18M | -24.15M | -23.14M | -45.88M | -56.3M | -69.6M | -30.8M | -32.9M |
| Operating Margin % | 11.91% | 17.61% | -13.53% | 9.09% | 1.55% | 42.99% | 22.93% | 670.99% | 65.11% | 48.25% | 40.27% | 38% | 30.41% | 30.51% | 1.83% | -2.32% | -124.5% | -25.6% | -356.13% | -466.69% | -119.73% | -14.99% | -22.86% | -13.59% | -24.99% | -30.31% | -95.37% | -137.65% | -393.22% | -59.57% | -89.4% |
| Operating Income Growth % | - | 308.79% | -289.3% | 293.22% | -97.08% | 176.94% | -95.35% | 392.94% | 140.51% | 55.12% | 60.58% | 39.25% | 31.34% | 2503.31% | 182.23% | 97.62% | -194.01% | 89.75% | -61.66% | 64.34% | -537.57% | 29.17% | -94.86% | 20.59% | -4.38% | 49.57% | 18.5% | 19.11% | -125.97% | 6.38% | -32.13% |
| EBITDA | 27.96M | 80.97M | 12.63M | 48.46M | 46.43M | 154.8M | 65.47M | 850.81M | 178.44M | 79.79M | 55.17M | 29.96M | 22.28M | 17.61M | 3.3M | 2.09M | -27.09M | -6.83M | -96.22M | -57.56M | -152.55M | -7.76M | -22.1M | -4.9M | -13.68M | -16.56M | -38.91M | -48.9M | -61.9M | -21M | -23.5M |
| EBITDA Margin % | 11.02% | 30.2% | 7.56% | 36.91% | 23.66% | 64.09% | 40.03% | 707.34% | 70.97% | 56.55% | 50.63% | 41.66% | 34.53% | 35.95% | 10.52% | 6.96% | -115.1% | -17.55% | -352.28% | -446.41% | -108.22% | -4.4% | -13.51% | -3.47% | -14.15% | -21.7% | -80.88% | -119.56% | -349.72% | -40.62% | -63.86% |
| EBITDA Growth % | -45.93% | 540.97% | -73.93% | 4.38% | -70.01% | 136.45% | -92.31% | 376.79% | 123.64% | 44.61% | 84.19% | 34.43% | 26.56% | 433.35% | 57.79% | 107.72% | -296.49% | 92.9% | -67.17% | 62.27% | -1864.88% | 64.86% | -351.12% | 64.19% | 17.42% | 57.43% | 20.43% | 21% | -194.76% | 10.64% | -10.85% |
| D&A (Non-Cash Add-back) | 26.05M | 33.77M | 35.24M | 36.52M | 43.39M | 50.95M | 27.97M | 43.73M | 14.72M | 11.71M | 11.29M | 2.63M | 2.66M | 2.66M | 2.73M | 2.79M | 2.21M | 3.13M | 1.05M | 2.62M | 16.22M | 18.71M | 15.28M | 14.28M | 10.47M | 6.57M | 6.97M | 7.4M | 7.7M | 9.8M | 9.4M |
| EBIT | 54.48M | 158.96M | 5.55M | 64.32M | 37.81M | 91.82M | 28.71M | 832.38M | 221.61M | 68.63M | 20.8M | 27.33M | 20.71M | 15.98M | 1.22M | 254K | -15.35M | -9.6M | -97.31M | -52.72M | -78.08M | -43.63M | -15.38M | -74.02M | -43.85M | -23.14M | -45.88M | -61.29M | -69.6M | -30.8M | -32.9M |
| Net Interest Income | 17.66M | 8.94M | 5.02M | 7.05M | 247K | -18.73M | -19.34M | -7.32M | -34.28M | -11.4M | -12.18M | -11.8M | -4.86M | -2.08M | -2.92M | -2.3M | 382K | 316K | 1.96M | 7.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 22.94M | 13.66M | 8.05M | 7.71M | 2.05M | 886K | 8.08M | 28.43M | 14M | 0 | 0 | 0 | 0 | 0 | 381K | 31K | 440K | 586K | 2.16M | 8.65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 5.28M | 4.71M | 3.04M | 656K | 1.8M | 19.62M | 27.41M | 35.74M | 48.28M | 11.4M | 12.18M | 11.8M | 4.86M | 2.08M | 3.31M | 2.51M | 58K | 270K | 202K | 735K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 22.49M | 111.76M | 25.12M | 51.72M | 32.97M | -31.65M | -36.21M | -10.44M | 9.6M | -10.85M | -35.92M | 8M | -8.32M | -5.74M | -4.44M | -2.86M | 13.9M | 95K | -239K | 6.72M | -96.19M | -9.87M | -7.54M | -20.39M | -8.36M | -8.36M | -825K | -707K | -43M | -61.3M | 3.7M |
| Pretax Income | 52.73M | 158.96M | 2.52M | 63.66M | 36.01M | 72.2M | 1.29M | 796.64M | 173.33M | 57.23M | 7.96M | 35.33M | 11.3M | 9.21M | -3.87M | -2.93M | -15.4M | -9.87M | -97.52M | -53.46M | -174.27M | 36.34M | -44.91M | -37.46M | -32.6M | -31.5M | -46.71M | -62M | -112.6M | -92.1M | -29.2M |
| Pretax Margin % | 20.77% | 59.29% | 1.51% | 48.48% | 18.35% | 29.89% | 0.79% | 662.31% | 68.93% | 40.56% | 7.3% | 49.13% | 17.51% | 18.8% | -12.31% | -9.75% | -65.44% | -25.35% | -357% | -414.58% | -123.63% | 20.58% | -27.46% | -26.54% | -33.73% | -41.26% | -97.08% | -151.59% | -636.16% | -178.14% | -79.35% |
| Income Tax | 1.27M | 34.51M | 6.55M | 9.84M | 41.23M | -4.15M | -5.31M | 167.34M | 30.01M | 44.67M | 10.33M | -219.6M | 410K | 374K | -1.19M | -13.1M | -2.62M | -7.92M | -55K | -18.7M | -38.41M | 59K | 233K | 18.28M | 8.45M | 19.86M | 26.49M | 18.4M | 48.3M | 69.4M | 4.4M |
| Effective Tax Rate % | 2.41% | 21.71% | 260.13% | 15.46% | 114.49% | -5.74% | -410.68% | 21.01% | 17.31% | 78.06% | 129.74% | -621.57% | 3.63% | 4.06% | 30.82% | 447.2% | 16.99% | 80.27% | 0.06% | 34.98% | 22.04% | 0.16% | -0.52% | -48.81% | -25.91% | -63.04% | -56.72% | -29.68% | -42.9% | -75.35% | -15.07% |
| Net Income | 51.46M | 124.45M | -4.03M | 52.15M | -33.36M | 57.14M | -2.98M | 629.3M | 143.32M | 12.56M | -1.64M | 257.31M | 12.02M | 11.42M | -527K | 10.18M | -12.52M | -1.95M | -98.11M | 281.69M | -31.74M | -36.4M | -45.14M | -37.46M | -32.6M | -42.99M | -72.38M | -74.7M | -117.9M | -100.2M | -37.3M |
| Net Margin % | 20.27% | 46.42% | -2.41% | 39.72% | -17% | 23.66% | -1.82% | 523.19% | 57% | 8.9% | -1.5% | 357.8% | 18.63% | 23.32% | -1.68% | 33.88% | -53.17% | -5% | -359.19% | 2184.64% | -22.52% | -20.61% | -27.61% | -26.54% | -33.73% | -56.32% | -150.44% | -182.64% | -666.1% | -193.81% | -101.36% |
| Net Income Growth % | 5.93% | 3186.63% | -107.73% | 256.33% | -158.39% | 2014.17% | -100.47% | 339.09% | 1041.45% | 867.48% | -100.64% | 2039.93% | 5.28% | 2267.17% | -105.18% | 181.31% | -542.45% | 98.01% | -134.83% | 987.4% | 12.79% | 19.37% | -20.5% | -14.93% | 24.19% | 40.59% | 3.11% | 36.64% | -17.66% | -168.63% | 41.9% |
| Net Income (Continuing) | 51.46M | 124.45M | -4.03M | 53.82M | -5.22M | 76.35M | 6.6M | 629.3M | 143.32M | 12.56M | -2.37M | 227.44M | 10.89M | 8.83M | -2.67M | 9.71M | -12.79M | -8.34M | -97.46M | -34.76M | -56.59M | -36.03M | -45.14M | -94.47M | -52.26M | -42.99M | -59.28M | -74.72M | -117.9M | -100.2M | -37.3M |
| Discontinued Operations | 0 | 0 | 0 | -1.67M | -28.14M | -19.21M | -9.58M | 0 | 0 | 0 | 731K | 0 | 0 | 2.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.91M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 2.58 | 6.13 | -0.22 | 2.94 | -1.98 | 3.34 | -0.18 | 31.85 | 5.96 | 0.53 | -0.08 | 12.12 | 0.56 | 0.55 | -0.03 | 0.52 | -0.64 | -0.10 | -6.16 | 17.22 | -2.36 | -2.95 | -3.68 | -3.18 | -2.83 | -4.34 | -7.80 | -9.51 | -17.51 | -18.15 | -7.78 |
| EPS Growth % | 8.21% | 2886.36% | -107.48% | 248.48% | -159.28% | 1955.56% | -100.57% | 434.4% | 1024.53% | 775.16% | -100.65% | 2064.29% | 1.82% | 2175.47% | -105.1% | 181.25% | -540% | 98.38% | -135.77% | 829.66% | 20% | 19.84% | -15.72% | -12.37% | 34.79% | 44.36% | 17.98% | 45.69% | 3.53% | -133.29% | 54.74% |
| EPS (Basic) | - | 6.44 | -0.22 | 3.02 | -1.98 | 3.46 | -0.18 | 33.13 | 5.96 | 0.60 | -0.08 | 13.00 | 0.59 | 0.56 | -0.03 | 0.52 | -0.64 | -0.10 | -6.16 | 17.22 | -2.36 | -2.95 | -3.68 | -3.18 | -2.83 | -4.34 | -7.80 | -9.51 | -17.51 | -18.15 | -7.78 |
| Diluted Shares Outstanding | 19.96M | 20.29M | 18.29M | 17.76M | 16.87M | 17.25M | 16.18M | 19.76M | 24.07M | 23.48M | 20.83M | 21.23M | 21.43M | 20.75M | 19.85M | 19.71M | 19.61M | 18.86M | 15.92M | 16.35M | 13.44M | 12.34M | 12.28M | 11.78M | 11.52M | 9.9M | 9.28M | 7.86M | 6.73M | 5.52M | 4.8M |
| Basic Shares Outstanding | 19.96M | 19.34M | 18.29M | 17.3M | 16.87M | 16.63M | 16.18M | 19M | 24.05M | 21.03M | 20.83M | 19.79M | 20.42M | 20.31M | 19.1M | 19.66M | 19.61M | 18.86M | 15.92M | 16.35M | 13.44M | 12.34M | 12.28M | 11.78M | 11.52M | 9.9M | 9.28M | 7.86M | 6.73M | 5.52M | 4.8M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 89.72% | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying LGND stock.
For fiscal year 2025, Ligand Pharmaceuticals Incorporated (LGND) reported total revenue of $268.1M. This represents a 628.5% increase compared to $36.8M in 1996.
Ligand Pharmaceuticals Incorporated (LGND) is profitable, generating $124.5M in net income for the fiscal year ending 2025 with a net profit margin of 46.4%.
Ligand Pharmaceuticals Incorporated (LGND) reported an operating income of $47.2M, resulting in an operating profit margin of 17.6%. This margin reflects the operational efficiency of the business before interest and taxes.
Ligand Pharmaceuticals Incorporated (LGND) generated $261.5M in gross profit for the year, representing a gross profit margin of 97.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Royalty concentration in few assets
Metrics are mathematically derived from official filings.
Revenue Volatility Masks Underlying Royalty Momentum
Based on reported quarterly figures, LGND's revenue swung from $115.5M in Q3 2025 to $51.7M in Q1 2026, a pattern suggesting milestone timing and lumpy royalty recognition rather than a steady compounding trajectory.
The sequential swings indicate that headline revenue is heavily influenced by one-time milestone and Veklury-related items rather than a smooth royalty base. The management-cited 32% royalty growth year over year may reflect a firmer underlying trend, but the quarterly series alone does not confirm durable acceleration. Investors should monitor whether the Q2 2026 level of $63.7M can be sustained without further milestone support.
Gross Margin Structurally High, Operating Margin Thin
Reported gross margins of roughly 93% to 97% in most recent quarters, against operating margins swinging between -20.0% and 33.6%, suggest that the royalty model carries high gross economics but substantial and variable operating overhead.
The gap between gross and operating margin points to a cost base that is not scaling with the revenue line, which limits the operating leverage the royalty structure would otherwise imply. Quarters with negative operating margins likely reflect acquisition-related or R&D-type spending rather than core royalty erosion. The durability of the margin profile therefore depends on whether overhead can be held flat as revenue fluctuates.
Net Income Diverges Sharply From Operating Results
According to the reported income statement, LGND's Q3 2025 net income of $117.3M far exceeded its $54.9M operating income, and the Q2 2026 net margin of 76.2% also outpaces its 13.5% operating margin, suggesting large non-operating contributions.
Net income in several quarters appears driven by items below operating income, such as gains, tax effects, or other non-operating items, rather than core royalty earnings. Reported EPS therefore may overstate recurring earnings power in those periods. Analysts should strip these items out and rely on operating income or cash flow to assess the underlying profit base.
Stock Compensation Consumes Significant Earnings Capacity
Stock-based compensation ran at $18.2M in Q3 2026 and $13.7M in Q2 2026, which is material relative to quarterly operating income of $8.6M in Q2 2026, implying equity compensation absorbs a meaningful portion of the operating profit base.
Elevated stock-based compensation relative to operating income suggests that reported operating performance flatters the cash-economic cost of running the platform. Management's expense discipline appears uneven, with R&D spiking to $50.1M in Q1 2025 before falling sharply. Investors may wish to model SBC as a real cost when assessing sustainable margins.
Concentration Risk Could Undermine the Growth Narrative
Based on the supplied data, LGND's recent growth depends heavily on a small number of royalty assets, and a Q3 2026 operating loss of $15.8M following a Q2 2026 profit shows how quickly the earnings picture can reverse.
The bear case centers on whether recent royalty growth from Filspari and Veklury is durable once milestone and pandemic-era tailwinds fade. The swing to a -36.2% net margin in Q3 2026 suggests the earnings base is not yet stable enough to rely on single-quarter guidance. Warrants further investigation into the duration of key royalty streams before extrapolating the current growth rate.